These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8962214)

  • 1. CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipients.
    van Besouw NM; Vaessen LM; Balk AH; Mochtar B; Claas FH; Weimar W
    Transplant Proc; 1996 Dec; 28(6):3135-6. PubMed ID: 8962214
    [No Abstract]   [Full Text] [Related]  

  • 2. Major histocompatibility complex-expressing human cardiac myocytes are not the direct target of host cardiac-infiltrating cells: evidence for a prominent role of the indirect pathway in human cardiac allograft rejection.
    Ansari AA; Kanter K; Wang YC; Mayne A; Sell KW; Herskowitz A
    Transplant Proc; 1993 Feb; 25(1 Pt 1):89-93. PubMed ID: 8438502
    [No Abstract]   [Full Text] [Related]  

  • 3. Late acute cardiac allograft rejection: new therapeutic options?
    Schweiger M; Wasler A; Prenner G; Tripolt M; Schwarz M; Tscheliessnigg KH
    Transplant Proc; 2005 Dec; 37(10):4528-31. PubMed ID: 16387161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection.
    Cosenza CA; Cramer DV; Eiras-Hreha G; Cajulis E; Wang HK; Makowka L
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):57-8. PubMed ID: 8516945
    [No Abstract]   [Full Text] [Related]  

  • 5. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4(+) T cells.
    Kapessidou Y; Habran C; Buonocore S; Flamand V; Barvais L; Goldman M; Braun MY
    Transplantation; 2006 Mar; 81(5):726-35. PubMed ID: 16534475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
    J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
    Katznelson S; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Terasaki PI; Kobashigawa JA
    J Heart Lung Transplant; 1998 Apr; 17(4):335-40. PubMed ID: 9588577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P; Asberg A; Guldseth H; Bremer S; Akhlaghi F; Reubsaet JL; Pfeffer P; Hartmann A; Midtvedt K
    Transplantation; 2008 Jan; 85(2):179-84. PubMed ID: 18212621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Additive immunosuppressive effect of hydroxycamptothecin and cyclosporine on rejection of heart transplantation in rats.
    Shi B; Cai M; Qian Y; Zhou W; Mo C; Wang Y
    Transplant Proc; 2007 Dec; 39(10):3429-31. PubMed ID: 18089398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is sensitivity to cyclosporine influenced by the HLA-DR phenotype of kidney graft recipients?
    Kyriakopoulos G; Antoniadis A; Gakis D; Papanikolaou V
    Transplant Proc; 1996 Dec; 28(6):3294-5. PubMed ID: 8962278
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine mitigates graft coronary artery disease in murine cardiac allografts: description and validation of a novel fully allogeneic model.
    Tanaka M; Mokhtari GK; Balsam LB; Cooke DT; Kofidis T; Zwierzchonievska M; Robbins RC
    J Heart Lung Transplant; 2005 Apr; 24(4):446-53. PubMed ID: 15797747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ; Rossi AF; Courtney M; Gelb BD
    J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of everolimus on cyclosporine Neoral pharmacokinetics in Chinese de novo cardiac transplant recipients.
    Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
    Transplant Proc; 2006 Sep; 38(7):2032-4. PubMed ID: 16979990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation.
    Aumente MD; Arizón JM; Segura J; López A; Albornoz R; Cárdenas M; Segura C
    Transplant Proc; 2005 Nov; 37(9):4014-7. PubMed ID: 16386613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
    Cai Y; Tang XD; Zhou PJ
    Scand J Immunol; 2005 Mar; 61(3):266-73. PubMed ID: 15787744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The replacement of graft endothelium by recipient-type cells conditions allograft rejection mediated by indirect pathway CD4+ T cells.
    Kapessidou Y; Habran C; Buonocore S; Flamand V; Barvais L; Goldman M; Braun MY
    Transplantation; 2006 Aug; 82(4):582-91. PubMed ID: 16958183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporine monitoring in pediatric allograft recipients--time for a change!
    Hoyer PF
    Pediatr Transplant; 2004 Apr; 8(2):101-3. PubMed ID: 15049787
    [No Abstract]   [Full Text] [Related]  

  • 18. Evidence that cyclosporin A prevents clinical cardiac allograft rejection by blocking both direct and indirect antigen presentation pathways.
    van Besouw NM; Vaessen LM; Knoop CJ; Balk AH; Mochtar B; Claas FH; Weimar W
    Transpl Int; 1996; 9 Suppl 1():S345-7. PubMed ID: 8959861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free bone graft attenuates acute rejection and in combination with cyclosporin a leads to indefinite cardiac allograft survival.
    Wang H; Ge W; Arp J; Zassoko R; Liu W; Ichim TE; Jiang J; Jevnikar AM; Garcia B
    J Immunol; 2009 May; 182(10):5970-81. PubMed ID: 19414748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.